Project Details
Description
The overarching goal of the study is to confirm the therapeutic activity of the human ARTOS lead candidate in huTNFR2-k/i mice. These studies are necessary to support clinical development of ARTOS, in particular for CMC development and to plan the DRF and TOX study as well as the clinical dosing.
| Acronym | ARTOS |
|---|---|
| Status | Active |
| Effective start/end date | 01/01/2023 → 01/01/2025 |